

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/972,177	10/05/2001	Laura C. Blumberg	PC11076A	3739
23913 7	590 07/29/2003			
PFIZER INC 150 EAST 42ND STREET 5TH FLOOR - STOP 49			EXAMINER	
			COLEMAN, BRENDA LIBBY	
NEW YORK, NY 10017-5612			ART UNIT	PAPER NUMBER
			1624	
			DATE MAILED: 07/29/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/972,177	BLUMBERG ET AL.				
Office Action Summary	Examiner	Art Unit				
	Brenda L. Coleman	1624				
The MAILING DATE of this communication appears on the cover shet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS fror cause the application to become ABANDON	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	<u> </u>					
	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) \boxtimes Claim(s) <u>1-14</u> is/are pending in the application						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-14</u> are subject to restriction and/or election requirement. Application Papers						
9)☐ The specification is objected to by the Examiner	r. ·	·				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Exa	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents	•					
2. Certified copies of the priority documents	s have been received in Applica	tion No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				
S. Patent and Trademark Office TO-326 (Rev. 04-01) Office Act	ion Summary	Part of Paper No. 2				



Application/Control Number: 09/972,177

Art Unit: 1624

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-14, drawn to the compounds, compositions and method of use of the compounds of formula I where the ring formed is 3,8-diazabicyclo[3.2.1]oct-8-yl, classified in class 544, subclass 349 and class 514, subclass 249.
- II. Claims 1-14, drawn to compounds, compositions and method of use of the compounds of formula I where the ring formed is 3,8-diazabicyclo[3.2.1]oct-3-yl, classified in class 544, subclass 349 and class 514, subclass 249.
- III. Claims 1-14, drawn to compounds, compositions and method of use of the compounds of formula I where the ring formed is 8-aza-bicyclo[3.2.1]oct-8-yl, classified in class 546, subclasses 125 and 132 and class 514, subclass 304.
- IV. Claims 1-4 and 6-14, drawn to compounds, compositions and method of use of the compounds of formula I where the ring formed is 2,5-diazabicyclo[2.2.2]oct-2-yl, classified in class 544, subclass 349 and class 514, subclass 249.
- V. Claims 1-14, drawn to compounds, compositions and method of use of the compounds of formula I where the ring formed is 3,9-diaza-

Art Unit: 1624

bicyclo[3.3.1]non-9-yl, classified in class 544, subclass 349 and class 514, subclass 249.

VI. Claims 1-14, drawn to compounds, compositions and method of use of the compounds of formula I where the ring formed is different from those listed in Groups I-V, classified in classes 544 and 546 and various subclasses within,

The inventions are distinct, each from the other because of the following reasons:

Groups I-VI are directed to structurally dissimilar compounds such that the variable core created by the varying definitions of W, k, I and m formula I do not belong to a recognized class of chemical compounds in the art, and references anticipating one invention, would not render obvious the others, for example a 3,8-diazabicyclo[3.2.1]oct-8-yl compound is different from a 3,8-diazabicyclo[3.2.1]oct-3-yl compound, an 8-aza-bicyclo[3.2.1]oct-8-yl compound a 2,5-diaza-bicyclo[2.2.2]oct-2-yl compound, a 3,9-diaza-bicyclo[3.3.1]non-9-yl compound, etc. Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support separate patents. The compounds differ significantly in chemical structures. One skilled in the art would not consider such diverse structures as functional equivalents of each other. The mere fact that there is a single similarity is not in itself a significant reason to render the whole embodiment obvious.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record



Art Unit: 1624

showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

If Group VI is elected further restriction may be required.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Groups II-V, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 703-305-1880. The examiner can normally be reached on 8:30-5:00 Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers





Application/Control Number: 09/972,177

Art Unit: 1624

for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Brenda Coleman

Primary Examiner Art Unit 1624

July 25, 2003